Bactericidal activity of BMY-28100 versus amoxicillin/clavulanic acid against Branhamella catarrhalis

BMY-28100 (Bristol-Myers, Belgium) is a new, orally absorbed cephalosporin that has an increased antibacterial spectrum compared to other cephalosporins and stability in the presence of beta-lactamase. The authors determined the bactericidal activity of BMY-28100 versus amoxicillin/clavulanic acid a...

Full description

Saved in:
Bibliographic Details
Published in:European journal of clinical microbiology & infectious diseases 1988-06, Vol.7 (3), p.433-434
Main Authors: Yourassowsky, E, Van der Linden, M P, Lismont, M J, Crokaert, F
Format: Article
Language:English
Subjects:
Amoxicillin - pharmacology
Amoxicillin-Potassium Clavulanate Combination
Branhamella catarrhalis
Cefprozil
Cephalosporins - pharmacology
Clavulanic Acids - pharmacology
Drug Combinations - pharmacology
Drug Resistance, Microbial
Humans
Moraxella catarrhalis - drug effects
Moraxella catarrhalis - isolation & purification
Respiratory Tract Infections - microbiology
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:BMY-28100 (Bristol-Myers, Belgium) is a new, orally absorbed cephalosporin that has an increased antibacterial spectrum compared to other cephalosporins and stability in the presence of beta-lactamase. The authors determined the bactericidal activity of BMY-28100 versus amoxicillin/clavulanic acid against ten beta-lactamase producing strains of Branhamella catarrhalis isolated from endoscopic or transtracheal aspiration from patients with bronchopulmonary infections.
ISSN:0934-9723
DOI:10.1007/BF01962359